SCHEMBL1360123

SCHEMBL1360123

Cc1nccn1-c1nc(-c2ccc(Cl)cc2)c(CCCOc2ccccc2C(C)C)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 2/20 0.33
GCGR P47871 1/20 0.33
POLB P06746 1/20 0.33
PPARD Q03181 2/20 0.33
L3MBTL1 Q9Y468 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
RECQL P46063 1/20 0.32
KMT2A Q03164 1/20 0.32
TNK2 Q07912 1/20 0.32
TP53 P04637 1/20 0.32
HTR1A P08908 2/20 0.32
HTR7 P34969 2/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361418 0.90 MAPT (0.42) LMNAMAPTGCGRPOLBL3MBTL1
SCHEMBL1361745 0.89 POLB (0.38) MAPTGCGRPOLBPPARDL3MBTL1
SCHEMBL203742 0.89 TP53 (0.41) ALDH1A1LMNAMAPTGCGRPOLB
SCHEMBL1361746 0.88 GCGR (0.38) MAPTGCGRPOLBL3MBTL1TDP1
SCHEMBL962882 0.88 MAPT (0.36) ALDH1A1LMNAMAPTGCGRPOLB
Hydrochloric Acid SCHEMBL1362475 0.88 TP53 (0.41) ALDH1A1LMNAMAPTGCGRPOLB
SCHEMBL1361779 0.87 GCGR (0.34) ALDH1A1LMNAMAPTGCGRPOLB
SCHEMBL1362923 0.86 MAPT (0.42) ALDH1A1LMNAMAPTGCGRPOLB
SCHEMBL1362902 0.86 GCGR (0.35) ALDH1A1MAPTGCGRPOLBL3MBTL1
SCHEMBL1363057 0.85 MAPT (0.39) ALDH1A1LMNAMAPTGCGRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 ALDH1A1 937/4885LMNA 4637/4885MAPT 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.